البلد: سنغافورة
اللغة: الإنجليزية
المصدر: HSA (Health Sciences Authority)
INDAPAMIDE; PERINDOPRIL TERT-BUTYLAMINE
SERVIER (S) PTE LTD
C09BA04
1.25 mg
TABLET
INDAPAMIDE 1.25 mg; PERINDOPRIL TERT-BUTYLAMINE 4 mg
ORAL
Prescription Only
LES LABORATOIRES SERVIER INDUSTRIE
ACTIVE
1999-03-24
1 QUALITATIVE AND QUANTITATIVE COMPOSITION Boxes of 30 tablets dosed at 4 mg of perindopril tert- butylamine and 1.25 mg of indapamide. THERAPEUTIC INDICATIONS Treatment of essential hypertension. COVERSYL PLUS is indicated for patients whose blood pressure is insuffi- ciently controlled by perindopril alone. DOSAGE AND METHOD OF ADMINISTRATION Oral route One tablet of COVERSYL PLUS per day as a single dose, preferably taken in the morning and before a meal. If necessary, dose titration with the individual components may be recommended. In appropriate clinical cases, a direct change from monotherapy to COVERSYL PLUS may be considered. _RENAL INSUFFICIENCY (SEE SPECIAL WARNINGS AND SPECIAL_ _PRECAUTIONS FOR USE)._ In cases of severe renal insufficiency (creatinine clearance below 30 ml/min), treatment is contra-indicated. In patients with a creatinine clearance greater than or equal to 30 ml/min and less than 60 ml/min, it is recommended to start the treatment with the adequate dosage of the free combination. It is not necessary to change the dose when the creatinine clearance is greater than 60 ml/min. The normal medical practice includes periodic control for creatinine and potassium. _CHILDREN_ COVERSYL PLUS should not be used in children as the efficacy and tolerability of perindopril in children, alone or in combination, have not been established. CONTRA-INDICATIONS _LINKED TO PERINDOPRIL_ This drug SHOULD NEVER be used in cases of: • hypersensitivity to perindopril, or to any other angiotensin converting enzyme inhibitor, • previous history of angineurotic oedema (Quincke's oedema) linked to treatment with an angiotensin converting enzyme inhibitor, • hereditary or idiopathic angioneurotic oedema, • pregnancy, • lactation. This drug is generally not recommended in: • combinations with potassium-sparing diuretics, potassium salts, lithium (See Interactions with other drugs and other forms of interactions), • bilateral renal artery stenosis or single functioning kidney اقرأ الوثيقة كاملة
1 QUALITATIVE AND QUANTITATIVE COMPOSITION Boxes of 30 tablets dosed at 4 mg of perindopril tert- butylamine and 1.25 mg of indapamide. THERAPEUTIC INDICATIONS Treatment of essential hypertension. COVERSYL PLUS is indicated for patients whose blood pressure is insuffi- ciently controlled by perindopril alone. DOSAGE AND METHOD OF ADMINISTRATION Oral route One tablet of COVERSYL PLUS per day as a single dose, preferably taken in the morning and before a meal. If necessary, dose titration with the individual components may be recommended. In appropriate clinical cases, a direct change from monotherapy to COVERSYL PLUS may be considered. _RENAL INSUFFICIENC_ _Y (SEE SPECIAL WARNINGS AND SPECIAL_ _PRECAUTIONS FOR USE)._ In cases of severe renal insufficiency (creatinine clearance below 30 ml/min), treatment is contra-indicated. In patients with a creatinine clearance greater than or equal to 30 ml/min and less than 60 ml/min, it is recommended to start the treatment with the adequate dosage of the free combination. It is not necessary to change the dose when the creatinine clearance is greater than 60 ml/min. The normal medical practice includes periodic control for creatinine and potassium. _CHILDREN_ COVERSYL PLUS should not be used in children as the efficacy and tolerability of perindopril in children, alone or in combination, have not been established. CONTRA-INDICATIONS _LINKED TO PERINDOPRIL_ This drug SHOULD NEVER be used in cases of: • hypersensitivity to perindopril, or to any other angiotensin converting enzyme inhibitor, • previous history of angineurotic oedema (Quincke's oedema) linked to treatment with an angiotensin converting enzyme inhibitor, • hereditary or idiopathic angioneurotic oedema, • pregnancy, • lactation. This drug is generally not recommended in: • combinations with potassium-sparing diuretics, potassium salts, lithium (See Interactions with other drugs and other forms of interactions), • bilateral renal artery stenosis or single functioning kidney, • hyperkalaemia _LINKE اقرأ الوثيقة كاملة